The discovery that tissue plasminogen activator can promote neuronal degeneration has uncovered a novel pathway leading to neuronal cell death and raises important issues concerning the use of tissue plasminogen activator as a thrombolytic therapy for stroke.
Ischemic stroke is one of the most common causes of neurological damage in humans and is usually the result of a clot blocking one of the blood vessels supplying the brain. Clots are broken down by plasmin, which is generated from its inactive precursor, plasminogen, by tissue plasminogen activator (tPA). Clot-busting therapy using tPA, if administered within three hours of an ischemic stroke, appears to benefit patients [1] . Recent observations on tPA-deficient mice, however, suggest that the use of tPA as a thrombolytic agent in stroke therapy might be a double-edged sword [2] .
While re-establishing blood flow in ischemic regions will certainly help reduce neuronal cell death, the work of Strickland's group [2] raises concerns that exogenously administered tPA may be partly responsible for killing neurons too. Although, in humans, the balance already appears to favour the early use of thrombolytic therapy, the issues raised by the new findings need to be addressed. Apart from the immediate clinical considerations, work on the tPA-deficient mice has shed new light on wholly novel pathways which may contribute to neuronal degeneration.
What is excitotoxicity?
The death of neurons is central to most pathologies of the central nervous system (CNS) and, as there is little scope for regeneration in the CNS, neuronal degeneration is responsible for lasting disability. Developing strategies to protect neurons from injury is thus likely to be of benefit in a wide variety of neurodegenerative conditions. To develop such strategies, we need a better understanding of the processes that lead to neuronal cell death.
Neuronal cell death is observed after excessive excitation of ionotrophic glutamate receptors by glutamate or related amino acids and has given rise to the 'excitotoxicity hypothesis' [3] . Within the CNS, it is mainly glutamate that mediates fast excitatory neurotransmission. Normally, released glutamate is quickly cleared from the extra-cellular space by energy-dependent processes, and the neurons are left uninjured. However, in situations where excessive glutamate is released and uptake mechanisms have been compromised, as may happen during an ischemic event in the brain, exposure to glutamate can be neurotoxic.
There are three main subtypes of ionotrophic glutamategated channels, which have been named according to their preferred agonist: N-methyl-D-aspartate (NMDA), kainate, and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA). In vivo, kainate is far more potent than glutamate when it comes to inducing excitotoxicity in the normal brain, because it is not cleared as rapidly as glutamate. The NMDA receptors, however, are thought to be the principal mediators of excitotoxicity, as they are permeable to Na + , K + and Ca 2+ ions. Only a small subset of AMPA or kainate channels are permeable to Ca 2+ ions, a property that has been shown to be critical for rapid-onset excitotoxicity in vitro. Indeed, the activation of kainate receptors is thought to result in secondary activation of the NMDA receptors, as experiments with antagonists have demonstrated that blockade of both NMDA and AMPA/kainate receptors is required to prevent rapidonset, kainate-induced cell death.
According to the excitotoxicity hypothesis, glutamate receptor activation to neuronal cell death is thought to take the following path: receptor activation leads to Na + influx to the neuron; voltage-gated Ca 2+ channels open in response to Na + influx; intra-cellular Ca 2+ levels rise and the cells physically swell; and lastly, there is inappropriate activation of many Ca 2+ -dependent catabolic processes that result in neuronal cell death by a mixture of apoptosis and necrosis [4] . Clearly, the jump from Ca 2+ influx to cell death is a big one, and it is one that remains poorly understood. Interest has centred on the activation of intraneuronal Ca 2+ -dependent proteases (such as the calpains [5] ), endonucleases [6] , phospholipases [7] and caspases [8] , and on the generation of free radicals [9] . Few researchers have considered that there might be extraneuronal processes involved.
The proteolytic cascade hypothesis
The observations of Strickland and colleagues over the past few years look likely to establish a role for extra-neuronal processes in excitotoxicity ( Figure 1 ). They found that 'knockout' mice lacking tPA are resistant to excitotoxin-mediated hippocampal neuronal degeneration [10] . tPA is produced primarily by microglia, the down-regulated resident macrophages of the brain. As mentioned above, tPA converts plasminogen to plasmin, which in turn degrades fibrin, fibronectin and laminin. Plasmin also processes many of the matrix-degrading metalloproteinases from pro-forms to active-forms. Thus, the observations on the tPA-deficient mouse implicate an extracellular proteolytic cascade in excitotoxin-induced cell death and suggest that microglia are important in the degeneration process.
To demonstrate that the resistance observed in the tPAdeficient knockout mice is unlikely to be a consequence of abnormal postnatal development, tPA was infused bilaterally into the hippocampus of the mutant mice, which were then injected with kainate [11] . In the presence of kainate and tPA, hippocampal neurons degenerated, but no degeneration was observed in the opposite hemisphere. Furthermore, 3 H-kainate binding to the hippocampus in tPA-deficient mice was indistinguishable from wild-type mice, indicating that the same number of receptors are present [12] .
It remained unclear, however, whether the substrate for tPA in the brain is, as expected, plasminogen. In a further set of experiments, Tsirka et al. [12] went on to show that mice deficient for plasminogen are also resistant to excitotoxic injury. Interestingly, tPA-deficient mice exhibit attenuated microglial activation, as determined by unaltered levels of F4/80 surface antigen, as a reaction to kainate-induced neuronal injury. In contrast, the microglial response of plasminogen-deficient mice is comparable to that of wild-type mice, suggesting the existence of a tPA-mediated, plasminogen-independent pathway for activation of microglia.
The resistance to excitotoxic injury of plasminogendeficient mice implies that substrates of the enzyme's product plasmin are likely to be important components of excitotoxicity. Fibrin looks unlikely to be the plasminogen substrate that mediates excitotoxicity, as fibrinogen knockout mice are still susceptible to kainate-induced excitotoxicity [12] . Further evidence for the involvement of a proteolytic cascade in excitotoxicity comes from inhibitor studies. Inhibitors of tPA (plasminogen activator inhibitor) [11] and plasmin (α2-antiplasmin) [12] have both been shown to inhibit kainate-induced excitotoxicity in wild-type mice. Although Strickland and colleagues have focused their studies on the hippocampus, our own studies suggest a more general applicability; α2-antiplasmin will reduce kainate-induced cell death in the striatum of the rat (unpublished observations).
The case for microglial involvement in excitotoxicty has been strengthened by the recent observations that macrophage inhibitory factor (MIF) will also block excitotoxin-induced neuronal cell death [13] . Microglial cells in the presence of MIF, infused into the hippocampus, fail to become activated following injection of kainate -as they normally would [14] -and produce less tPA in response to lipopolysaccharide (a further treatment that normally stimulates microglia activation). The data thus implicate microglia as being key players in excitotoxic cell death.
How do activated microglia cause neuronal cell death? It is known that such cells, within inflammatory lesions in the brain, synthesise matrix metalloproteinases [15] . This family of endopeptidases, which contain Zn 2+ at the active site and are Ca 2+ -dependent, are able to degrade all of the components of the extracellular matrix [16] , and can process the precursor of the inflammatory cytokine tumour necrosis factor-α (TNF-α) to its mature, soluble form [17] . Direct injection of highly purified matrix metalloproteinases -such as gelatinase-A, gelatinase-B or matrilysin -into the striatum of rats results in demyelination and neuronal cell death [18] . The mechanism by which this is achieved is unknown, but we have shown that gelatinase-B is extensively expressed within acute stroke lesions [15] . In all the cases we examined, there was a marked infiltration of gelatinase-B-positive neutrophils and some macrophages within the infarcted tissue. There was also increased expression of both gelatinase-A and matrilysin within the chronic stroke lesions, and this persists for up to five years after the original ischemic event. Their presence in the chronic lesions Dispatch R275
Figure 1
The proteolytic cascade hypothesis. Excitotoxins, acting through glutamate receptors, provoke the release of tPA from activated microglia and neurons. The released tPA is then able to convert inactive plasminogen to plasmin. Plasmin, in turn, can degrade laminin and activate the 'pro' forms of the matrix metalloproteinases, which are synthesised by microglia. Disruption of laminin-neuron interactions results in neuronal degeneration. Excessive matrix metalloproteinase release may be cytotoxic in itself or, as is more likely, may cause neuronal degeneration by disrupting the extracellular matrix. suggests that there might be on-going neuronal degeneration long after a stroke.
Both plasmin and many of the matrix metalloproteinases, including matrilysin, can degrade laminin. In studies by Chen and Strickland [19] , where the expression of various extracellular proteins before and after excitotoxic lesions was examined, it was found that laminin may be of critical importance in excitoxicity. Their principal findings were as follows. First, laminin disappears rapidly after the injection of excitotoxin and before neuronal loss. Second, tPA-deficient mice display minimal laminin loss following kainate injection. And third, anti-laminin antibody injection, which interferes with neuron-laminin interactions, leads to neuronal degeneration in the absence of tPA. As the anti-laminin antibodies caused neuronal degeneration, rather than just promoting it, these results suggest that disruption of the extracellular environment of a neuron is enough to cause degeneration.
It would be interesting to know whether the phenomenon observed by Chen and Strickland [19] is specific to laminin-neuron interactions, or whether the disruption or degradation of other extracellular matrix proteins might also result in neuronal cell death. The extracellular matrix of the adult brain tissue has a unique composition in that the typical matrix proteins, such as collagen, are nearly absent. Instead, the brain extracellular matrix is mainly composed of lecticans, which are proteoglycans containing a lectin domain and a hyaluronic-acid-binding domain [20] . Thus, the disruption of the various lectican-neuron interactions might also result in neuronal degeneration.
Therapeutic implications
Clearly, the proteolytic cascade hypothesis of neuronal cell death suggests novel strategies for therapeutic intervention. Inhibitors of plasmin/tPA, of microglial activation, and of matrix metalloproteinases may all have practical therapeutic potential. However, consideration of the implications for existing stroke therapy is more urgent. Thrombolytic therapy for acute ischemic stroke has been approached cautiously, because there were high rates of intracerebral haemorrhage in early clinical trials. If the therapy is administered outside the three-hour window, a dramatic increase in the risk of intracerebral haemorrhage is present. Even if the therapy is given within three hours of the ischemic event, a small increase in the rate of intracerebral haemorrhage has been noted [1] . As tPA is involved in the cascade that processes promatrix metalloproteinases to the active forms, the administration of tPA at a time when the number of matrix-metalloproteinase-expressing leucocytes is increasing might be significant in activating and promoting the destructive potential of these enzymes, thereby leading to haemorrhage.
The recent observations of Strickland and colleagues now suggest that administration of tPA to stroke patients might not only increase the risk of haemorrhage but, on entering the CNS, might potentiate neuronal degeneration. Indeed, Wang et al. [2] have shown that tPA infused into wild-type mice will increase the size of an ischemic lesion. Although it is tempting to extrapolate to the clinical situation, we should remember that pre-clinical studies in stroke therapy have not readily translated to the clinic. However, the development of new tPA-based thrombolytic drugs, which are active only at the site of the clot, might be of benefit.
The experiments described above draw attention to some new areas of investigation. Now, the role of the tPA cascade, the nature of the proteases that are activated, and the nature of their substrates all need to be defined. The new studies also add further weight to the evidence that microglia are directly involved in neuronal cell death. The dementia associated with AIDS has been linked to the neurotoxic substances secreted by HIV-1-infected microglia [21] . Furthermore, in the developing CNS, the secretion of nerve growth factor (NGF) by microglia might be neurotoxic [22] . Finally, the unusual extracellular matrix of the CNS has been implicated in the regenerative response of the CNS [23] , but these experiments indicate that it might be involved in the modulation of neuronal activity.
